Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925253 | 0.86 | TRPV4 (0.41) | TRPV4HDAC1HDAC6 | |
| SCHEMBL30668 | 0.73 | HDAC1 (0.48) | HDAC1HDAC6 | |
| SCHEMBL67360 | 0.73 | RAPGEF4 (0.42) | HDAC1HDAC6 | |
| SCHEMBL2096368 | 0.73 | TRPV4 (0.50) | TRPV4 | |
| SCHEMBL18673225 | 0.73 | HDAC1 (0.42) | HDAC1HDAC6 | |
| SCHEMBL16707503 | 0.69 | HDAC1 (0.39) | HDAC1HDAC6 | |
| SCHEMBL19876048 | 0.69 | HDAC1 (0.31) | HDAC1HDAC6 | |
| SCHEMBL29306263 | 0.69 | TRPV4 (0.33) | TRPV4HDAC1HDAC6 | |
| SCHEMBL23348689 | 0.69 | HDAC1 (0.31) | HDAC1HDAC6 | |
| SCHEMBL9192230 | 0.69 | RAPGEF4 (0.35) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210619-A1 | 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis | MERCK SERONO SA (CH) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210619-A1 | 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis | S1PR1, S1PR5, S1PR3 | TRPV4 799/4885HDAC1 2239/4885HDAC6 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.